2 results about "Erlotinib" patented technology

This invention, entitled "Combined Application and Product of BAM-15 and Erlotinib," belongs to the field of combined antitumor drug application technology. The technical problem it aims to solve is the low response and limited efficacy of existing erlotinib monotherapy to EGFR wild-type lung adenocarcinoma, and the lack of effective targeted intervention options in clinical practice. The key points of the technical solution are: combining BAM-15 and erlotinib for the interventional treatment of EGFR wild-type lung adenocarcinoma; the combination produces a significant synergistic effect, with tumor suppression superior to the additive effect of using either drug alone, without antagonistic effects, effectively enhancing the inhibitory effect on EGFR wild-type lung adenocarcinoma and enriching clinical treatment options for tumors.